InMed Pharmaceuticals (INM) Cash & Equivalents (2020 - 2026)

InMed Pharmaceuticals' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 10.64% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 10.64% increase from a year earlier, with the FY2025 full-year figure at $10.7 million, up 63.48% from the prior year.
• Cash & Equivalents declined to $5.2 million in Q1 2026 per INM's latest filing, from $7.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.5 million in Q4 2022 and bottomed at $1.2 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $6.6 million (2024), against an average of $6.8 million.
• Across the five-year window, Cash & Equivalents plunged 88.58% in 2023 and jumped 654.43% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $11.5 million in 2022, then plunged by 88.58% to $1.3 million in 2023, then soared by 232.28% to $4.3 million in 2024, then soared by 61.06% to $7.0 million in 2025, then decreased by 25.71% to $5.2 million in 2026.
• Per Business Quant, the three latest INM Cash & Equivalents figures stand at $5.2 million (Q1 2026), $7.0 million (Q4 2025), and $9.3 million (Q3 2025).